37 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27789141	58	II. Discovery of a novel series of CXCR3 antagonists with a beta amino acid core.	Sanofi
27789137	63	I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines.	Sanofi
27692854	100	N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.	Boehringer Ingelheim Pharmaceuticals
26862767	40	Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3.	Friedrich-Alexander University
24486132	38	IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.	Merck Research Laboratories
19299127	55	Exploring a pocket for polycycloaliphatic groups in the CXCR3 receptor with the aid of a modular synthetic strategy.	Vu University Amsterdam
21570852	84	CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors.	Vu University Amsterdam
23150943	43	Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands.	Vu University Amsterdam
22931505	69	Chemokine receptor antagonists.	National Heart And Lung Institute
18337097	64	Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3.	Abbott Bioresearch Center
18068363	19	Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolines.	Ucb Pharma
18242988	37	Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.	Abbott Bioresearch Center
18063364	68	Design and optimization of imidazole derivatives as potent CXCR3 antagonists.	Amgen
17448658	53	Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.	Amgen
22130135	55	Discovery of potent and specific CXCR3 antagonists.	Amgen
22018463	40	III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold.	Merck Research Laboratories
21764306	149	Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.	Novartis Institutes For Biomedical Research
21277198	71	II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.	Ligand Pharmaceuticals
20483605	47	Discovery of a novel series of CXCR3 antagonists.	Merck Serono
19632842	65	Optimization of a series of quinazolinone-derived antagonists of CXCR3.	Amgen
20004096	49	Identification of a new class of small molecule C5a receptor antagonists.	Wyeth Research
19647429	35	Novel CXCR3 antagonists with a piperazinyl-piperidine core.	Ligand Pharmaceuticals
19631529	74	Imidazo-pyrazine derivatives as potent CXCR3 antagonists.	Amgen
19783143	65	Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.	Novartis Institutes For Biomedical Research
18922694	84	Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.	Johnson & Johnson Prd
19014886	83	Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.	Glaxosmithkline
18061451	35	Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.	Amgen
18032038	38	Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.	Ucb Pharma
17964154	27	Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.	Ucb Pharma
17097877	40	Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.	Ucb Pharma
16213722	36	Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.	Pharmacopeia Drug Discovery
15911279	9	Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.	Vrije Universiteit Amsterdam
16950396	13	Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.	Osaka University Of Pharmaceutical Sciences
10956222	105	Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).	University Of Auckland